• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Monogram Technologies Inc.

    9/12/25 3:16:11 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email
    DEFA14A 1 tm2525993d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

     

    x  Filed by the Registrant ¨  Filed by a Party other than the Registrant

     

    CHECK THE APPROPRIATE BOX: 
    ¨

    Preliminary Proxy Statement

    ¨

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨

    Definitive Proxy Statement

    x 

    Definitive Additional Materials

    ¨ 

    Soliciting Material Under §240.14a-12

     

    Monogram Technologies Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

    x

    No fee required

    ¨

    Fee paid previously with preliminary materials

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    On September 12, 2025, the following communication was sent to stockholders of Monogram Technologies Inc.

     

    Dear {{record_holder}},

     

    We’d like to inform you of two important items that need your consideration.

     

    1.You still have an opportunity to move your shares from us to your brokerage firm should you wish to (i) streamline payment of the applicable merger consideration upon consummation of Zimmer Biomet Holdings, Inc.’s proposed acquisition of Monogram Technologies Inc. (“Monogram”) or (ii) trade your shares prior to the consummation. To do so, please log into your account at my.equitystock.com.

     

    ·If your DRS transfer fee has not been paid, and you would like to move your shares to your brokerage firm, then you can make the payment directly through our platform at my.equitystock.com. There is no requirement to move your shares. If you have any questions regarding your shares, please visit our FAQ.

     

     

    ·If your DRS transfer fee has been paid or is indicated as “Not Applicable”, then there are no payment stops on your shares. You can generate your DRS statement and send it to your brokerage firm, and they will handle the transfer. You can trade your shares through your brokerage firm should you desire.

     

     

     

     

    To generate your DRS statement:

     

     

     

    Please note: Instructions on how to transfer your shares to your broker are posted on our FAQ.

     

    2.Monogram is holding a special meeting of shareholders on September 30, 2025, and your vote matters. If you have not already voted and would like to review the company’s proposal and cast your vote, please go to www.monogram.vote, click VOTE YOUR PROXY, and enter {{proxy_voting_code}}, which is your unique Proxy Voting Code.

     

     

     

     

     

    When you’re in the “Proposal” screen, please cast your vote for the two proposals and remember to click SUBMIT.

     

     

    If you have already voted, then you can disregard the above and click Register to attend Monogram Technologies 2025 Special Meeting to pre-register to attend the special meeting.

     

    You are reminded that your Board of Directors unanimously recommends that you vote FOR the Merger and related proposals.

     

    Monogram urges you to cast your vote TODAY. Remember, not voting will have the same effect as voting against the Merger. Your vote is important no matter how many shares you own.

     

    Thank you for being a valued shareholder of Monogram Technologies. Should you have any questions regarding your shares or on how to vote, please visit the Monogram FAQ. Should you require any further support, please email: [email protected].

     

    Sincerely,

     

    Shareholder Services

    Equity Stock Transfer

    www.equitystock.com

     

    Disclaimer:

     

    Important Information and Where to Find It

     

    This communication relates to the proposed transaction involving Monogram Technologies Inc. (“Monogram”) and Zimmer Biomet Holdings, Inc. In connection with the proposed transaction, Monogram has filed with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A (the “Proxy Statement”). This communication is not a substitute for the Proxy Statement or any other document that Monogram may file with the SEC or send to its stockholders in connection with the proposed transaction. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

     

     

     

    Get the next $MGRM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Riss Paul H

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    9/30/25 5:06:32 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Unis Douglas

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    9/30/25 5:05:22 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Technology Officer Shamaei Kamran

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    9/30/25 5:04:27 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Monogram Technologies with a new price target

    ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

    12/9/24 7:59:36 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    View All

    Monogram Accepted to NVIDIA Inception Program

    Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

    4/11/24 1:20:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Reports First Quarter 2025 Financial Results

    Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

    5/14/25 4:01:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

    11/12/24 8:31:00 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    SEC Filings

    View All

    Monogram Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Monogram Technologies Inc. (0001769759) (Filer)

    9/30/25 5:15:51 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Monogram Technologies Inc.

    DEFA14A - Monogram Technologies Inc. (0001769759) (Filer)

    9/12/25 3:16:11 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 425 filed by Monogram Technologies Inc.

    425 - Monogram Technologies Inc. (0001769759) (Subject)

    9/5/25 7:58:22 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

    The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient. The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clin

    7/29/25 9:30:05 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

    7/22/25 9:15:00 AM ET
    $AGEN
    $CLOV
    $MGRM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Medical/Dental Instruments